

## Division of Clinical Therapeutics

B. Timothy Walsh, MD, Division Chief

Department of Psychiatry, Columbia University College of Physicians and Surgeons

New York State Psychiatric Institute

Annual Report for July 1, 2007 – June 30, 2008

### Overview

The division of Clinical Therapeutics was officially created on July 1, 2007, by joining the following divisions and units: Anxiety Disorders Clinic, Anxiety Genetics Unit, Biological Studies Unit, Center for Neuroinflammatory Disorders and Biobehavioral Medicine/ Lyme Disease, Clinical Psychopharmacology, Depression Evaluation Service and the Eating Disorders Research Unit.

**Anxiety Disorders Clinic:** The Anxiety Disorders Clinic (ADC) was established in 1982 to study the diagnosis, pathophysiology, and treatment of anxiety disorders. The clinic has grown over the years and now includes programs in obsessive-compulsive disorder, posttraumatic stress disorder and related traumatic conditions (Trauma and PTSD program), social anxiety disorder, generalized anxiety disorder, anxiety and depression in Hispanic Americans (Hispanic Treatment Program), pathological gambling, and anxiety and depression in patients seen in primary care and other medical specialties. Studies include effectiveness trials in community settings, efficacy trials in specialty clinics, biological studies (e.g., brain imaging studies, translational studies) investigating pathophysiology, as well as epidemiological and health services research.

The Anxiety Disorders Clinics mission is to improve the outcome of its patients by the development and study of new therapeutic strategies, the dissemination of evidence-based practices to clinicians and patients, and the elucidation of the brain mechanisms underlying their symptoms. The clinic is examining pharmacotherapy, psychotherapy (cognitive-behavioral therapy, interpersonal therapy, motivational interviewing), and complementary medicine approaches. It is conducting a variety of brain imaging studies in collaboration with colleagues in other Divisions using a range of techniques (e.g., positron emission tomography, magnetic resonance spectroscopy, functional magnetic resonance imaging). It is also conducting epidemiological and services research.

**Anxiety Genetics Unit:** The Anxiety Genetic Unit originated as the component of the NYSPI Anxiety Disorders Clinic responsible for the diagnostic and family studies. In collaboration with Jean Endicott the unit developed research instruments for lifetime assessment of anxiety disorders and symptoms and conducted some of the first family studies of social and specific phobias. In 1987 the unit expanded its work to include a DNA marker linkage study of panic disorder and have since become a separate research group with a specific focus on understanding genetic contributions to human

anxiety and anxiety disorders. The unit's work involves both collaborations on traditional family/linkage studies and neurobiologically based "endophenotypic" and "translational" approaches genetic studies of anxiety.

**Biological Studies Unit:** The Biological Studies Unit (BSU), in addition to conducting its own research program (BSU Clinical Psychobiology), also maintains a centralized research laboratory, serving the need of investigators throughout the Medical Center. Current protocols at the BSU Psychobiology Program include a sequential treatment study, including both psychotherapy and medications guided by patient choice, sponsored by NIMH for older patients with Generalized Anxiety Disorder. Another project is designed to develop a novel administration of an anti-panic drug using a laboratory paradigm. The immediately acting form of this medication could potentially prevent panic attacks in patients with panic disorder. Pharmacological treatment trials and biological challenge studies with levetiracetam and tiagabine have been completed during the reporting period and the results have been presented at national and international scientific meetings and are being prepared for publication.

**The Center for Neuroinflammatory Disorders and Biobehavioral Medicine:** The Center for Neuroinflammatory Disorders and Biobehavioral Medicine (CNDBBM) was established in 2007, with historical predecessors to 1994 when the Somatic Disorders Program and the Lyme Disease Research Program were established. The CNDBBM studies diseases that fall within the domain of neuroinflammatory disorders, biobehavioral medicine, and neuropsychiatry. Also in 2007, the University-wide Lyme and Tick-borne Diseases Research Center was established – a joint effort among Columbia University, Time for Lyme, Inc, and the Lyme Disease Association, Inc. The opening of the Center was celebrated by a symposium with speakers including C. Ben Beard (Chief, Vector Borne Diseases, CDC) and Ian Lipkin (Director, Laboratory for Immunopathogenesis and Infectious Diseases). Primary areas of disease focus have been Lyme disease, hypochondriasis, and most recently refractory psychosis. Targets of study include humans and ticks. Studies include efficacy trials, diagnostic, biomarker, neuroimaging, and molecular research.

**Clinical Psychopharmacology:** The research efforts of Clinical Psychopharmacology have focused on depression, reward systems and their comorbidity. Areas of interest include: biological characteristics and treatment modalities in patients with late-life depression; the relationship of depression to the development of cardiac mortality/morbidity; and smoking dependence, with special interest in the relationship between nicotine addiction and depression, as well as the prevention of smoking relapse.

**Depression Evaluation Services:** The Depression Evaluation Service (DES) was formed in 1977 by Dr. Frederick Quitkin, who sadly succumbed to cancer in October 2005, at which time Drs. Patrick J. McGrath and Jonathan W. Stewart were appointed Co-Directors to succeed him. The mission of the DES, consistent with Dr. Quitkin's vision, has been to study diagnosis, pathophysiology, and treatment in mood disorders and related problems using therapeutic response as a nosologic tool. The DES' work

has led to major developments in the field of psychiatry, including the addition of an “atypical” subtype of mood disorders in the DSM-IV.

The department also initiated studies predicting relapse after successful treatment with serotonin reuptake inhibitor antidepressant medications, treating depression when it co-occurs with alcohol or drug dependence, and investigating genetic predictors of antidepressant medication response, among other accomplishments. In addition, it conducted longitudinal cohort studies exploring the emergence or exacerbation of depression in terminally ill patients with cancer, amyotrophic lateral sclerosis, or AIDS.

The DES participated significantly in the design and execution of “Sequenced Treatment Alternatives to Relieve Depression” (STAR\*D), a major NIMH clinical trial which was completed last year. Since September 2007, the DES has been collaborating with sites in Ottawa and Hull, Canada, to complete “Combining Antidepressants to Hasten Remission from Depression,” evaluating the advantage of using two antidepressants in combination over either medication alone. Patients in this trial optionally participate in Dr. Gerald Bruder’s studies attempting to correlate psychophysiologic measures with treatment outcomes in individuals with depression. Dr. Rabkin’s group has also been actively working with colleagues in the Department of Neurology ALS Clinic, conducting collaborative studies of depression prevalence, as well as an intervention to treat fatigue.

**Eating Disorders Research Unit:** The Eating Disorders Research Unit was founded by Dr. B. Timothy Walsh nearly 30 years ago. Currently under the direction of Dr. Evelyn Attia, the EDRU conducts research and offers treatment for individuals with anorexia nervosa, bulimia nervosa, binge eating disorder and associated conditions. During the most recent academic year, the EDRU has included 12 faculty members and 2 post-doctoral research fellows, all of whom are involved in the division’s scientific enterprise along with other academic activities conducted throughout the medical center. The EDRU works closely with the General Clinic Research Unit at NYSPI to offer specialized clinical services to eating disorder patients interested in and eligible for research participation.

## Staff

Director

B. Timothy Walsh, MD, Psychiatrist III

Deputy Directors

Evelyn Attia, MD, Psychiatrist II

Brian A. Fallon, MD, Psychiatrist II

Abby Fyer, MD, Psychiatrist Research II

Alexander Glassman, MD, Research Scientist VIII

Patrick McGrath, MD, Psychiatrist Research II

Laszlo Papp, MD, Psychiatrist Research II

Helen Blair Simpson, MD, Research Scientist VI  
Jonathan Stewart, MD, Psychiatrist Research II

#### Professional Staff

Vito Agosti, M.S.W., Research Scientist III  
Susanne Ahmari MD, Postdoctoral Clinical Fellow  
Nicole Barbarich-Marsteller, PhD, Assistant Professor of Neurobiology (in Psychiatry)  
James Bender Jr, PsyD, Research Project Manager II  
Tatyana, Biyanova PhD Clinical Researcher I  
Carlos Blanco, MD, PhD, Psychiatrist II  
Sarah Black, M.A., Research Project Manager I  
Allegra Broft, MD, Assistant Professor of Clinical Psychiatry  
Raphael Campeas, MD, Psychiatrist Research II  
Ying Chen, MD, Research Scientist II  
Kathy Corbera, MD, Senior Staff Associate  
Lirio S. Covey, PhD, Research Scientist V  
Ana Alicia de la Cruz, M.A., Assistant Research Scientist II  
Deborah Deliyannides, MD, Psychiatrist Research II  
Michael J. Devlin, MD, Psychiatrist II  
Stephen Donovan, MD, Assistant Professor of Clinical Psychiatry  
Dawn Dugan, ABD, Diagnostic Interviewer  
Deborah R. Glasofer, PhD, Psychologist  
Juli A. Goldfein, PhD, Research Scientist IV  
Magdaliz Gorritz, MPH, Technical Specialist II  
David Hellerstein, MD, Psychiatrist Research III  
Marcela Hoffer, MD Research Scientist V  
Marilena Jennings MD Psychiatrist I Hospital  
Matthew Kaplowitz Ph.D Clinical Researcher I  
Ronit Kishon, PhD, Senior Research Worker  
Diane Klein, MD, Assistant Professor of Clinical Psychiatry  
Keng-Han Lin, M.S., Technical Specialist II  
Joshua Lipsitz, MD, Associate Professor of Clinical Psychiatry  
Shang-Min Liu, M.S., Technical Specialist II  
Roberto Lewis-Fernández, MD, Psychiatrist II Spanish Language  
Joshua Lipsitz, PhD, Associate Professor of Clinical Psychology (in Psychiatry)  
Michael Maher, PhD, Research Scientist II  
Laurel Mayer, MD, Psychiatrist II  
Martin McElhiney, PhD, Research Scientist II  
Michael McKee, PhD, Research Scientist III  
Diana Morrobel PhD Research Scientist V  
Yuval Neria, PhD, Research Scientist VI  
Edward V. Nunes, MD, Psychiatrist II  
Donna O'Shea, Ms.Ed, Program Coordinator  
Jessica Page, PhD, Research Scientist III  
Sapana Patel, PhD, Research Scientist II  
Elizabeth W. Persons, MPH, Research Worker

Daniel Pilowsky, MD, Psychiatrist II  
Anthony Pinto, PhD, Research Project Manager III  
Judith G. Rabkin, PhD, Research Scientist VI  
Richard Rabkin, MD, Psychiatrist III Hospital  
Pamela Raizman, PhD, Research Scientist III  
Carolyn Rodriguez, MD, PhD, Post Doctoral Clinical Fellow  
Bret Rutherford, MD, Postdoctoral Clinical Fellow  
José Arturo Sánchez-Lacay, MD, Psychiatrist II Spanish Language  
Janet Schebendach, R.D., Director of Research Nutrition  
Franklin Schneier, MD, Research Psychiatrist II  
Smit Sinha, MD, Assistant Professor of Clinical Psychiatry  
Natalia Skritskaya, PhD, Research Scientist I  
Jordan Slavov, PhD, Research Technician II  
Stephanie Sosa PhD Research Scientist II  
Joanna Steinglass, MD, Assistant Professor of Clinical Psychiatry  
Eun Jung Suh, PhD, Research Scientist II  
Julie Surbaugh, PsyD, Diagnostic Interviewer  
Robyn Sysko, PhD, Postdoctoral Research Fellow  
Sarah Trooper Olivo, M.A., Psychologist  
Donna Vermes, M.S., N.P.P., Psychiatric Nurse II  
Oriana Vesga Lopez, MD Research Scientist Level II  
Shuai Wang, PhD, Technical Specialist II  
Ellen Zimmerli, PhD, Assistant Clinical Professor of Psychology in Psychiatry

## **Current Research**

### **Anxiety Disorders Clinic**

OCD program: Dr. Simpson runs an interdisciplinary research program dedicated to improving the outcome of patients with OCD. She is currently using clinical trials methodology to study whether motivational interviewing can improve adherence to evidence-based OCD treatments (R34 funded by NIMH and NARSAD) and which augmentation strategies can lead to remission in OCD (R01 funded by NIMH). She is also using brain imaging methodology in collaboration with Dr. Anissa Abi-Dargham to determine whether patients with OCD have serotonergic abnormalities in specific brain areas (R01 funded by NIMH). Finally, she is collaborating with Drs. Rene Hen and Susanne Ahmari to develop translational models of OCD (R24 unfunded by NIMH). New directions include examining glutamate abnormalities in specific brain areas in collaboration with Dr. Larry Kegeles and testing novel medications for OCD in collaboration with Drs. Moira Rynn and Carolyn Rodriguez

Anxiety, Medical Illness and Addictions: Dr. Blanco runs a program that integrates epidemiology, treatment development, and efficacy and effectiveness studies in depression, anxiety and addictive disorders, with a focus on Hispanics. Funding for this program is provided by NIH, OASAS, and private foundations. In collaboration with Dr. Grann (Herbert Irving Comprehensive Cancer Center) he recently completed a study to

treat depressed women with breast cancer with interpersonal psychotherapy (IPT). An R01 has been submitted to NIH and got promising reviews.

Generalized Anxiety Disorder: Dr. Schneier is studying sequential treatment with cognitive-behavioral therapy and escitalopram.

Social Anxiety Disorder: Drs. Liebowitz and Blanco recently completed a multi-site study of cognitive-behavioral therapy and paroxetine. Dr. Schneier continued a study of brain circuitry responses to direct versus indirect eye gaze, before and after paroxetine treatment (R21 funded by NIMH, and he continued a collaboration with Dr. Gorenstein (Surgery) to study social anxiety in hyperhidrosis patients.

Depression: Dr. Schneier is studying D2 receptors and dopamine release in depressed patients (NARSAD Independent Investigator Award).

Trauma and PTSD program: Dr. Yuval Neria runs an interdisciplinary program aiming to 1) study psychosocial and biological factors involved in the development of PTSD and resilience and 2) to examine the efficacy of new treatments for PTSD. Current projects include: a clinical trial of Complicated Grief Treatment (CGT) for 9/11 Bereaved (Neria; SPUNK), 2) a CBT trial for returning war veterans (Neria; SPUNK); and 3) a comprehensive follow up study of primary care patients with PTSD (Neria; RO1; NIMH). 4) a study of combined treatment with paroxetine and cognitive behavioral therapy for 9/11-related PTSD (Schneier, NIMH RO1); an examination of the efficacy of IPT as compared to CBT and relaxation for patients with PTSD (Markowitz, NIMH; RO1). Pending grants include: Brain Mechanisms of Posttraumatic Stress Disorder (PTSD) and Resilience (Neria, Spunk); Psychotherapies for Chronic PTSD in Returning OIF/OEF Veterans (Markowitz, DOD); Brain Circuitry and Psychosocial Predictors of PTSD (Neria; NIMH); Internet-Based Intervention for Prolonged Grief Disorder among War Veterans (Neria; NIMH).

The Hispanic Treatment Program: Dr. Lewis-Fernández continued to conduct a) an R01 to test an intervention based on motivational interviewing to improve retention and treatment outcome in depressed Hispanics on antidepressant therapy; b) an R34 from NIMH on a novel approach based on the DSM-IV Cultural Formulation to help bridge the care of depressed Hispanic patients from primary care to specialty mental health services, and c) a project funded by the American Red Cross to provide medication and psychotherapy services to Hispanics still suffering from anxiety and depressive disorders as a result of 9/11. The program also completed an industry-sponsored clinical trial on the efficacy of lamictal monotherapy in the treatment of MDD with elevated somatization in Hispanic outpatients.

### **Anxiety Genetics Unit**

Dr. Fyer is continuing her work as part of a five site collaborative group studying genetic contributions to obsessive compulsive disorder. These investigators began subject recruitment for a new NIMH funded study to conduct a triad based whole genome

association study of OCD. With collaborators she continues to work on analyses of genetic and psychophysiologic data from studies of fear conditioning and panic disorder.

### **Depression Evaluation Service**

Dr. Jonathan Stewart is currently recruiting participants for an exciting NIMH-funded study of Major Depressive Disorder in adult outpatients, investigating whether the combination of antidepressant medications is superior in efficacy and speed of recovery to either medication alone.

Dr. David Hellerstein is recruiting participants for a state of the art study which includes fMRI imaging of patients with dysthymia before and after treatment with medication to examine the psychobiology of this disorder in a way never before explored.

Dr. Rabkin recently completed enrollment of 115 patients with HIV/AIDS and clinically significant fatigue in a placebo controlled trial of modafinil, and is now recruiting HIV+ patients with fatigue for a trial of armodafinil (the r-isomer of modafinil), evaluating fatigue levels, cognitive function and behavioral changes.

Dr. Donovan's research is investigating the pharmacology of addiction risk factors. While the current focus is on Attention Deficit Hyperactivity Disorder, Dr. Donovan seeks to research other treatable risk factors, as well. His method involves treating Attention Deficit Hyperactivity Disorder in younger siblings of adolescents who have developed substance abuse. An open label study of Vyvanse supported by Shire Pharmaceuticals is the first proof of concept test of this "younger sibling design."

### **The Center for Neuroinflammatory Disorders and Biobehavioral Medicine**

**Hypochondriasis:** Jointly with Dr. Arthur Barsky at Harvard University, the unit continues to conduct a five-year NIH-funded, dual-site treatment study of hypochondriasis, comparing CBT, Fluoxetine alone, FLX+CBT, and Placebo. This group is also conducting, with Dr. Kelli Harding as PI and Dr. Brad Peterson as Co-Investigator, a fMRI study of information processing using a virtual reality maze among patients with hypochondriasis versus healthy controls.

**Lyme Disease:** Several studies have been completed during this interval. (1) A study assessing the potential utility for differential diagnosis associated with brain SPECT imaging comparing Lyme disease, depression, and healthy controls. (2) A study evaluating the specificity of laboratory testing for Lyme disease at four different laboratories. (3) A study initiated with Dr. James Moeller to determine whether there is a neuro-imaging biomarker associated with Lyme encephalopathy. The Lyme group has also continued its collaborative work with Dr. Steven Schutzer of UMDNJ to conduct proteomic investigations of the CSF of patients with chronic Lyme disease.

**Psychosis:** Given recent pre-clinical work demonstrating that the antibiotic IV ceftriaxone is one of the most powerful up-regulators of the GLT1 glutamate transporter, Dr. Fallon, in collaboration with Dr. Lieberman and the Schizophrenia Research Unit, has continued his NARSAD-funded placebo-controlled study to investigate the potential

efficacy of IV ceftriaxone as a treatment for refractory psychosis. This study also has a MR spectroscopy component that is being conducted with Dr. Larry Kegeles, Dr. Shungu, and Dr. Peterson to look for changes in the glutamate/gaba spectra before and after treatment.

### **Clinical Psychopharmacology**

Alexander Glassman, in association with the Department of Medicine and School of Public Health, is completing a five-year follow-up of those patients who participated in the study of an SSRI vs. placebo in major depression following myocardial infarction. The initial results of this study were republished in JAMA in 2002. Although there was a trend for a reduction in life-threatening events the number of such events that occurred in six months was limited. With five years of follow-up over 21% of the sample have died. This study involves examining potential predictors of death. Baseline severity of depression and if the patients depression improved regardless of whether treated with drug or placebo predicted death, years later.

In collaboration with the division of geriatric psychiatry, important new developments in the Late-Life Depression Clinic include that Dr. Bret Rutherford, a research fellow, has begun a series of new studies to understand the impact of patient expectancy on outcome in antidepressant clinical trials. Joel Sneed continues projects as part of his K award to study diagnostic criteria for vascular depression. As part of this project this group has developed a collaboration with the Geriatric Division of Harlem Hospital and are going to be part of a NIMH multi-center study on the use of calcium channel blockers in patients with vascular depression. Unique meta-analyses by Drs. Sneed and Rutherford, both in press, have shown that study design, e.g. whether a patient is in a comparator study in which both patient and doctor know they are receiving an active treatment or are in a placebo-controlled study where they do not know whether they are receiving an active treatment, has a greater impact on outcome than medication itself. Drs. Gregory Pelton, Dev Devanand, and Steven Roose are close to completing the first study of whether the combination antidepressants and cognitive enhancers will decrease the rate of conversion of depressed patients with cognitive impairment to dementia.

Dr. Lirio Covey reported the main finding from her completed 5-year grant "Maintenance treatment for preventing smoking relapse," funded by the National Institute on Drug Abuse (NIDA), in the journal *Addiction*. Compared to the standard, eight-week duration of bupropion use as a smoking cessation aid, an additional 16 weeks of bupropion treatment prolonged time to relapse; the effect was modest (hazard ratio=0.59) but statistically significant. The study also found, however, that the relapse preventive effect did not last long after terminating bupropion use.

A second publication based on data from that trial was published in the Winter, 2008 issue of the journal, *Ethnicity and Disease*. The manuscript, "Smokers' response to bupropion, nicotine patch, and counseling by race/ethnicity" one of the first studies to investigate disparity in smoking cessation rates by race/ethnicity found that whereas 60% of white participants achieved 4-week continuous abstinence at the end of the 8-

week treatment, significantly lower proportions of African American and Hispanic participants (38% and 41% respectively) were able to do so. Another study, which Dr. Covey reported as an invited paper at the 2008 meeting in Rome, Italy, of the European affiliate of the Society for Research on Nicotine Tobacco found that, whereas smokers with elevated inattention symptoms achieved similar cessation rates as smokers not affected by symptoms of Attention Deficit Hyperactivity Disorder (ADHD), the subgroup with predominantly hyperactivity/impulsivity symptoms achieved significantly lower cessation rates in response to the treatment which consisted of open label bupropion, nicotine patch, and counseling. This study is scheduled for publication in the December, 2008 issue of Nicotine and Tobacco Research. Another forthcoming publication reports that given similarity in demographic, psychological, and smoking history, gay/bisexual smokers can benefit equally, if not more, than smokers of heterosexual orientation when using established treatments for smoking cessation.

Dr. Covey and her colleagues continued their participation as one of six sites in a multi-site, placebo-controlled pilot trial of OROS-methylphenidate as a smoking cessation aid for adult smokers with ADHD conducted by the Clinical Trials Network of NIDA. The NYSPI smoking cessation group conducted this study through the Long Island Regional Node of CTN-NIDA of which Dr. Edward Nunes is the Principal Investigator. The main study objective is to investigate the ability of OROS-MPH to improve smoking cessation outcome among smokers with ADHD when used as an adjunct to standard smoking cessation treatment, i.e., nicotine patch and individual behavioral counseling. A second main objective is to determine if OROS-MPH will improve ADHD symptoms in the sample of adult smokers. Three types of treatment facilities were selected for this pilot trial: community-based drug treatment, ADHD clinic, or smoking cessation clinic. The NYSPI site was selected, along with the Mayo Clinic's Nicotine Dependence Center, as a prototype of a smoking cessation facility.

### **Depression Evaluation Service**

Dr. Jonathan Stewart is currently recruiting participants for an exciting NIMH-funded study of Major Depressive Disorder in adult outpatients, investigating whether the combination of antidepressant medications is superior in efficacy and speed of recovery to either medication alone.

Dr. David Hellerstein is recruiting participants for a state of the art study which includes fMRI imaging of patients with dysthymia before and after treatment with medication to examine the psychobiology of this disorder in a way never before explored.

Dr. Rabkin recently completed enrollment of 115 patients with HIV/AIDS and clinically significant fatigue in a placebo controlled trial of modafinil, and is now recruiting HIV+ patients with fatigue for a trial of armodafinil (the r-isomer of modafinil), evaluating fatigue levels, cognitive function and behavioral changes.

Dr. Donovan's research is investigating the pharmacology of addiction risk factors. While the current focus is on Attention Deficit Hyperactivity Disorder, Dr. Donovan seeks to research other treatable risk factors, as well. His method involves treating

Attention Deficit Hyperactivity Disorder in younger siblings of adolescents who have developed substance abuse. An open label study of Vyvanse supported by Shire Pharmaceuticals is the first proof of concept test of this "younger sibling design."

### **Eating Disorders Research Unit**

New York State Center of Excellence: Under the direction of Dr. Evelyn Attia, the New York State Center of Excellence for Eating Disorders Treatment grant was renewed for an additional year. This Center, at New York Presbyterian Hospital in conjunction with NYSPI and Schneider Children's Hospital, is one of three identified Centers across New York State, and receives support from the NYS Department of Health, and aims to improve coordination of clinical services for patients with anorexia nervosa, bulimia nervosa and ED-NOS.

Bulimia Nervosa: The group continues a collaborative, translational research grant among several groups studying various aspects of eating regulation: researchers studying drug abuse/dependence (Dr. Richard Foltin), researchers studying peripheral controls of appetite and satiety in animals (Drs. Gary Schwartz, and Gerard Smith), and CNS reward mechanisms involved in eating. The purpose of this grant is to apply the concepts and methodology used by these other groups to study dysregulation of eating in humans. The bulimia nervosa team is studying reward pathways in humans with BN using Positron Emission Tomography (PET), as well as the reinforcing properties of binge behavior in BN utilizing a progressive task ratio conducted in a laboratory setting.

Anorexia Nervosa: The unit received support through the Clinical and Translational Science Award/Office of Clinical Trials at CUMC to support a study that aims to use functional neuroimaging (fMRI) to examine the functioning of the amygdala-ACC-PFC circuit in response to fearful and neutral faces and fearful and neutral (i.e. high and low calorie) foods and response to emotional conflict in the presence of food and non-food distractors (food and non-food Stroop tasks) in women with Anorexia Nervosa, before and after treatment. The unit is developing an exposure therapy/response prevention treatment for weight-restored individuals with anorexia nervosa aiming to prevent relapse. It completed a double blind trial of olanzapine for the outpatient treatment of AN, and presented promising findings from this study at the annual meeting of the Eating Disorders Research Society (EDRS). The unit continues to examine the phenomenon of exercise dependence in women with anorexia nervosa. It published the results of one study in patients with AN of the relative reinforcing value of exercise.

Binge Eating Disorder: This group is continuing to conduct laboratory studies of eating behavior in obese women with and without binge eating disorder. Finally, they are continuing to study the relationship between eating disorders, such as binge eating and night eating, and outcome in patients who have gastric bypass surgery for obesity.

Adolescent Obesity: In collaboration with the Department of Pediatrics and Pediatric Surgery the eating disorders group is continuing to study the psychological effects of bariatric surgery in overweight teens.

## Education and Training

**Anxiety Disorders Clinic:** The Anxiety Disorders Clinic also participates actively in the teaching and supervision of PGY-2, PGY-3, and PGY-4 psychiatric residents, and medical students, organizing and running several core classes (e.g., Anxiety Disorders Class for PGY-2 residents) and providing lectures (e.g., psychopharmacology of anxiety disorders, cognitive-behavioral therapy of anxiety disorders) in other core classes. Drs. Simpson, Amsel, and Schneier also delivered lectures for the Departmental Annual Review of Psychiatry.

**Anxiety Genetics Unit:** Dr. Fyer taught a short course o Research Methods to the PGYIV residents and is also working part-time with Dr.Anke Ehrhardt, Vice Chair for Faculty Affairs in the Office of Faculty Affairs.

**Biological Studies Unit:** The staff of the BSU actively participates in training programs for residents and fellows, including supervision of PGY-II and III residents in cognitive behavioral therapy, teaching in the PGY-II course in psychopharmacology, supervision of psychology interns in cognitive behavioral therapy and lecturing in the Seminar in Cognitive Behavior Therapy for psychology interns and in the Cognitive-Behavior Therapy course for PGY-III residents.

**The Center for Neuroinflammatory Disorders and Biobehavioral Medicine:** Dr. Kelli Harding completed her fellowship in Affective Disorders while working with the group. Two P&S Medical students completed an eight week summer fellowship during which they learned about neuropsychiatric disorders. Dr. Ella Doctoroff, family medicine physician, completed her eighteen month fellowship with the group during which she learned about Lyme and Tick Borne Diseases.

**Eating Disorders Research Unit:** The Eating Disorders Unit is actively involved in the training of medical students and residents, specifically in regular didactic and clinical case discussions conducted with the staff and trainees affiliated with the General Clinical Research Unit (GCRU)

## Clinical Services

The Lyme and Tick-Borne Diseases Evaluation Service is a two-day evaluation service for patients who have persistent neurological or neuropsychiatric symptoms that have been attributed to Lyme or another tick-borne disease. Patients are evaluated by a physician and extensive neurocognitive, blood and, if indicated, imaging and CSF tests are conducted. Recommendations are based on integrated information from the neuropsychological and clinical evaluation, medical records, and laboratory testing. Alternate diagnoses are considered and additional testing, referrals and/or symptomatic therapies may be recommended.

The Eating Disorders Assessment and Treatment Service (EDATS) offers comprehensive evaluations and treatment for patients with anorexia nervosa, bulimia nervosa, binge eating disorder and obesity. EDATS consultations are conducted by Columbia University faculty with extensive eating disorders expertise. Evaluations will include detailed feedback and treatment recommendations. Follow-up consultations may be arranged if needed. Available treatments include individual and group psychotherapy and medication management with Columbia University faculty. More structured treatment for individuals with eating disorders, including evidence-based psychotherapy groups and supervised meals is available at the Columbia Eating Disorders Program (CEDP), part of the Columbia University Day Program at East 60th Street. EDATS and CEDP are part of the Columbia Center for Eating Disorders and The New York State Comprehensive Care Center for Eating Disorders, Metropolitan Division. Under the founding leadership of Dr. B. Timothy Walsh and the current leadership of Dr. Evelyn Attia, The Columbia Center for Eating Disorders is an internationally recognized program with nearly thirty years of commitment to the research and treatment of eating disorders.

## New Grants

- Carlos Blanco, MD, Improving the Effectiveness of Treatment for Depression in Hispanics (1R01MH076051)
- Stephen J. Donovan, Pilot Study of Vyvanse in Adolescent with ADHD and Substance Abuse (Shire, Inc)
- Abby J. Fyer, MD, OCD Collaborative Genetics Association Study (5R01MH079488)
- Roberto Lewis-Fernandez, MD, Center for Cultural Competency (OMH)
- Roberto Lewis-Fernandez, MD, Motivational Antidepressant Therapy for Hispanics 5R01MH077226)
- Laszlo Papp, M.D, Development of Multimodal Treatment for Late Life Generalized Anxiety Disorder (5R34MH077156)
- H. Blair Simpson, MD, Building Translational Research in Obsessive-Compulsive Disorder (1R24MH080022)
- Joanna Steinglass, MD, Addressing Fear of Food in Anorexia Nervosa (5R01MH082736)
- Jonathan Stewart, MD, Combining Antidepressants to Hasten Remission from Depression (5R01MH076961)
- Smit Sinha, MD, A Randomized, Placebo Controlled Trial of Lunesta in the Treatment of Chronic Insomnia (Lunesta)
- B. Timothy Walsh, MD, Translational Research on Eating Disorders: Reward Systems (1R01MH079397)
- B. Timothy Walsh, MD, The Development of an Eating Laboratory for Overweight Adolescents (5R21DK074503)
- Laurel Mayer, MD, Understanding the Neural Circuitry of Eating Disorders (Astra Zeneca)

- Continuing Research
- Evelyn Attia, MD, Anorexia Nervosa: The Importance of Treatment Intensity (5R34MH070597)
- Evelyn Attia, MD, Gender Differences in CNS Serotonin Activity: Implications for Anorexia Nervosa (Pfizer, Inc)
- Carlos Blanco, MD, Substance Abuse in U.S. Hispanics: A National Study (5R01DA019606)
- Carlos Blanco, MD, SMART: Improving Detection & Outcome of Psychiatric Comorbidity in Drug Treatment (5R01DA020783)
- Brian A. Fallon, MD, Fluvoxamine in Hypochondriasis (Solvay)
- Brian A. Fallon, MD, Treatment of Hypochondriasis with CBT &/or SSRI (5R01MH071456)
- Alexander Glassman, MD, A 7 Week Double Blind Placebo Controlled, Randomized, Multi-Center Study Evaluating the Safety and Efficacy of 3 Doses (Pfizer, Inc)
- David Hellerstein, MD, Duloxetine for Chronic Depression: A Double Blind Study (Eli Lilly)
- Roberto Lewis-Fernandez, MD, Culturally Congruent Program of MDD Care for Hispanics (5R34MH073087)
- Roberto Lewis-Fernandez, MD, Open Trial of Lamotrigine in Latino Outpatient with Somatization and Major Depression
- Roberto Lewis-Fernandez, MD, Open Trial of Duloxetine in Outpatients with Irritable Bowel Syndrome and Co-Morbid Major Depression
- Roberto Lewis-Fernandez, MD, Training and Consultation-Liasion Program between Academic Psychiatrist and Community Based PMD's (Pfizer, Inc)
- Patrick McGrath, MD, A Trail in Subjects who Suffer from Major Depressive Disorder (Organon Pharmaceuticals, Inc)
- Yuval Neria, MD, Center for the Study of Trauma and Resiliency (Trauma Center)
- Yuval Neria, MD, Long Term Impact of WTC Attacks in Primary Care (R01 MH72833)
- Laslzo A. Papp, MD, Alprazolam Inhalation in Panic Disorder (Alexa Pharmaceuticals, Inc)
- Laslzo A. Papp, MD, A Double-Blind, Multicenter, Placebo-Controlled Study of L-830982 Gel Extrusion Module (GEM) 1.5 mg b.i.d. to 4.5 mg b.i.d in the Treatment of Outpatients of Generalized Anxiety Disorder (Merck Research Laboratories)
- Laslzo A. Papp, MD, A 12- Week Open-Label Followed by a 24-Week Double-Blind Discontinuation Exploratory Study to Evaluate the Effects of GABITRIL in Patients with Social Anxiety Disorder (Cephalon, Inc)
- Laslzo A. Papp, MD, Escitalopram for the Treatment of Patients with Panic Disorder and Comorbid Asthma (Forest Laboratories, Inc.)
- Laslzo A. Papp, MD, Keppra (Levetiracetam) and CO2 Sensitivity in Panic Disorder (UCB Pharma, Inc)

- Judith G. Rabkin, MD, Modafinil Treatment for Fatigue in HIV+ Patients (5R01MH072383)
- Franklin Schneier, MD, A Trial of Levetiracetam for the Treatment of Generalized Social Anxiety Disorder (UCB Pharma, Inc.)
- Franklin Schneier, MD, Combination Treatment for PTSD After the WTC Attack (5R01MH068173)
- Franklin Schneier, MD, Escitalopram Treatment of Major Depression and Comorbid Social Anxiety Disorder
- Franklin Schneier, MD, Neural circuitry of submissive behavior and treatment response in social anxiety (5R21MH077976)
- Franklin Schneier, MD, Cognitive-Behavioral Therapy and Pharmacotherapy Augmentation for Generalized Anxiety Disorder
- H. Blair Simpson, MD, Maximizing Treatment Outcome in OCD (5R01MH045436)
- H. Blair Simpson, MD, Imaging the Serotonin System in Obsessive-Compulsive Disorder (5R01MH073915)
- H. Blair Simpson, MD, Enhancing CBT Adherence in OCD with MI (5R34MH071570)
- Joanna Steinglass, MD, D-Cycloserine and Exposure Therapy in the Treatment of Anorexia Nervosa
- Jonathan Stewart, MD, A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depressives (Eli Lilly & Company)
- Jonathan Stewart, MD, Lamotrigine as an Antidepressant Augmentation Agent in Treatment Refractory Unipolar Depression (GlaxoSmithKline Research & Development Limited)
- B. Timothy Walsh, MD, A Study to Assess Topiramate in the Treatment of Moderate to Severe Binge-Eating Disorder Associated with Obesity (Ortho-McNeil)
- B. Timothy Walsh, MD, Placebo Response in Acute Mania (Abbot Laboratories)
- B. Timothy Walsh, MD, Psychobiology of Eating Behavior in Eating Disorders (5R01MH042206)
- B. Timothy Walsh, MD, Support Received for Training Session Entitled "Understanding Eating Disorders (GlaxoSmithKline Research & Development Limited)

#### K Awards

- Carlos Blanco, MD, Bridging Efficacy and Effectiveness in Drug Abuse Treatment
- Allegra Broft, MD, Clinical and Translational Science Award
- Diane Klein, MD, Excitatory Controls of Eating in Eating Disorders (5K23MH071285)
- Joanna E. Steinglass, MD, Cognitive Neuroscience of Anorexia Nervosa (5K23MH07619)
- Private Foundations & Grants
- Carlos Blanco, MD, ASFP: A National Study of Ethnic Difference in Suicide Ideation and Attempts

- Brian A. Fallon, MD, NARSAD: IV Certiaxone for Refractory Psychosis: A Controlled Trial
- Diane Klein, MD, NARSAD: Effects of Mifepristone in the Treatment of Anorexia Nervosa
- Yuval Neria, MD, Spunk, Inc: Mental Health Consequences of Disaster
- Yuval Neria, MD, Spunk, Inc: Promoting Recovery from Combat Stress Injury
- Franklin Schneier, MD, NARSAD: Amphetamine-Induced Dopamine Release in Striatal Subregion in Major Depressive Disorder
- H. Blair Simpson, MD, NARSAD: Using Motivational Interviewing to Enhance Treatment Outcome in Obsessive Compulsive Disorder
- Joanna Steinglass, MD, NARSAD: D-Cycloserine and Exposure Therapy – A Novel Approach in Anorexia Nervosa

#### Large Gifts Received

- PS 144, Forest Hills, NY
- Steward Rahr gift to the Eating Disorders Research Unit
- Sycamore Fund
- Taub Foundation (Suzanne Murphy)
- Time for Lyme, Inc

## Awards and Honors

Michael J. Devlin, MD elected to the Glenda Garney Teaching Academy in March 2008.

Brian Fallon, MD completed his term as president of the District Branch of the Connecticut Psychiatric Society (Fairfield and Litchfield Counties) and continues on its executive committee.

Dr. Fallon was also awarded the Nancy Roseke Certificate of Recognition for Medical Student Education at the May 2008 meeting of the American Psychiatric Association, Washington D.C.

Alexander Glassman, MD, was presented with the 21st Anna-Monika Prize by Monika Rief-Rehme, commemorating the symposium which was part of this year's DGPNN Congress in Berlin.

Roberto Lewis-Fernandez, MD was invited to join the Anxiety, Obsessive Compulsive Spectrum, Posttraumatic, and Dissociative Disorders Work Group of DSM-V. He also was named the Director of the OMH-sponsored Center of Excellence for Cultural Competence at NYSPI, which will conduct research on improving cultural competence of mental health services statewide. In addition, Dr. Lewis-Fernández received the Rafael Tavarez, MD Memorial Award from the Association of Hispanic Mental Health Professionals.

Yuval Neria, MD, received the 2007 NARSAD Klerman Award for Outstanding Clinical Research (Honorable Mention)

Edward V. Nunes, MD, was appointed Vice-Chairman of the NYSPI Institutional Review Board and was named among New York Magazine's Best Doctors.

Blair Simpson, MD, was nominated to be Vice-Chair the Scientific Advisory Board of the Anxiety Disorders Association of America Publication of the first Practice Guidelines for the Treatment of OCD produced by the American Psychiatric Association (Dr. Blair Simpson as one of the workgroup members)

B. Timothy Walsh, MD was elected president of the Eating Disorders Research Society

## **New Faculty**

Allegra Broft, MD was promoted to an Assistant Professor of Clinical Psychiatry

Sapana Patel, PhD was appointed to an Assistant Professor of Clinical Psychology (in Psychiatry).

## **Highlights**

The Center of Cultural Competence was established in October 2008 as a community outreach project in Northern Manhattan that will develop culturally competent, person-centered best practices for delivering physical health care to patients with serious mental illness. This project is being conducted in collaboration with diverse community stakeholders, including consumers, family members, providers, representatives of faith-based organizations and community residents.

For the Center for Neuroinflammatory Disorders and Biobehavioral Medicine, this year marked the publication of the clinical results from a major clinical trial on persistent Lyme encephalopathy. This paper, published in *Neurology*, reported that a repeated course of IV antibiotic therapy did not result in specific improvement in memory, as was expected. However, the results did indicate that repeated IV antibiotic treatment leads to moderate improvement in overall cognition and, among the more impaired, on secondary measures of fatigue, pain, and physical dysfunction. Further the study revealed that the moderate improvement in cognition was not durable to a six month end-point. The group concluded, therefore, that because of the risk of serious side effects, 10 weeks of IV ceftriaxone followed by no antibiotic treatment was not indicated for sustained improvement in cognition.

The Depression Evaluation Service opened a new clinic at 1775 Broadway last year, and the DES doctors have since been seeing patients regularly at this midtown location, giving patients who are unable to travel uptown access to the group's clinical trials.

## Publications

Agosti V, Stewart JW: Hypomania with and without dysphoria: comparison of comorbidity and clinical characteristics of respondents from a national community sample. *J Affect Disord* 2008;108:177-82

Agosti V, Stewart JW: Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression. *Int Clin Psychopharmacol* 2007;22:309-11

Aharonovich, E, Brooks, AC, Nunes, EV, Hasin, DS: Cognitive deficits in marijuana users: effects on motivational enhancement therapy plus cognitive behavioral therapy treatment outcome. *Drug Alcohol Depend* 2008; 95:279-283

Akerele, E, Bisaga, A, Sullivan, MA, Garawi, F, Comer, SD, Thomas, AA, Nunes, EV, Kleber, HD: Dextromethorphan and quinidine combination for heroin detoxification. *Am J Addict* 2008; 17:176-180

Arnaout B, Batchelder S, Rosenthal RN, Hyler S, Hellerstein DJ: Does a history of alcohol use disorder affect response to antidepressant medication in patients with dysthymic disorder? *J of Dual Diagnosis* 2008;4:377-393

Attia, E. Walsh BT, Anorexia Nervosa: *Am J Psychiatry*. 2007 Dec;164(12):1805-10; quiz 1922

Baca-Garcia E, Perez-Rodriguez MM, Keyes KM, Oquendo MA, Hasin DS, Grant BF, Blanco C. Suicidal ideation and suicide attempts in the United States: 1991-1992 and 2001-2002. *Mol Psychiatry* (in press)

Blanco C, Cohen O, Luján J, Wulfert E. Substance Abuse and Pathological Gambling. In: *Substance Dependence and Co-Occurring Psychiatric Disorders: Best Practices for Diagnosis and Treatment*. Nunes E, Selzer J, Levounis P, eds. Civic Research Institute, Inc., (in press)

Blanco, C, Harford, TC, Nunes, E, Grant, B, Hasin, D: The latent structure of marijuana and cocaine use disorders: Results from the National Longitudinal Alcohol Epidemiologic Survey (NLAES). *Drug Alcohol Depend* 2007; 91: 91-96

Blanco C, Olfson M, Goodwin RD, Ogburn E, Nunes E, Liebowitz MR, Hasin DS. Generalizability of clinical trials for depression to community samples. *J Clin Psychiatry*, 2008;69:1276-1280.

Blanco C, Grant JE, Petry NM, Alegría A, Simpson HB, Liu SM, Grant BF, Hasin DS. Prevalence and correlates of shoplifting in the US: Results of the National

Epidemiologic Survey for Alcohol and Related Conditions. *Am J Psychiatry*, 2008; 165:905-913

Blanco C, Ogburn E, Pérez de los Cobos JC, Lujan J, Nunes EV, Grant BF, Liu SM, Hasin DS. DSM-IV Criteria-Based Clinical Subtypes of Cannabis Use Disorders: Results From The National Epidemiological Survey on Alcohol and Related Conditions (NESARC). *Drug Alcohol Dep*, 2008; 96:136-144

Blanco C, Okuda M, Olfson M, Nunes E, Liu SM, Hasin DS. Generalizability of clinical trials for alcohol dependence to community samples. *Drug Alcohol Depend*, 2008 98:123-128

Blanco C, Okuda M, Wright C, Hasin DS, Grant BF, Liu SM Olfson M. Mental Health of College Students and Their Non-college-attending Peers: Results from the National Epidemiologic Study on Alcohol and Related Conditions. *Arch Gen Psychiatry* (in press).

Blanco C, Potenza MN, Kim SW, Ibáñez A, Zaninelli R, Sáiz-Ruiz J, Grant JE. A pilot study of impulsivity and compulsivity in pathological gambling. *Psychiatry Res* (in press)

Blanco C, Markowitz JC, Weissman MM. Interpersonal Psychotherapy. In: Gelder MG, Andreasen N, Lopez-Ibor JJ, eds. *The New Oxford Textbook of Psychiatry*. Oxford: Oxford University Press (in press).

Broft AI, Spanos A, Corwin RL, Mayer L, Steinglass J, Devlin MJ, Attia E, Walsh BT. Baclofen for binge eating: an open-label trial. *Int J Eat Disord*. 2007 Dec;40(8):687-91.

Broft A, Spanos A, Corwin RX, Mayer L, Steinglass J, Devlin, M, Attia E, Walsh BT. Baclofen as a novel treatment for binge eating: an open-label pilot study. *International Journal for Eating Disorders* 2007 Dec

Broft A, Berner, L, Martinez D, Walsh BT. The potential role for dopamine in bulimia nervosa: a brief review. In revision.

Bruder GE, Stewart JW, Schaller JD, McGrath PJ: Predicting therapeutic response to secondary treatment with bupropion: dichotic listening tests of functional brain asymmetry. *Psychiatry Research* 2007; 153: 137–143

Carpenter, KM, Smith, JL, Aharonovich, E, Nunes, EV: Developing therapies for depression in drug dependence: results of a stage 1 therapy study. *Am J Drug Alcohol Abuse* 2008; 34: 642-652

Charon R, Wyer P, NEBM Working Group. The art of medicine. Narrative evidence based medicine. *Lancet* 371:296-297, 2008.

Choy C, Schneier FR, Heimberg RG, Oh K-S, Liebowitz MR: Features of the Offensive Subtype of Taijin-Kyofu-Sho in U.S. and Korean patients with DSM-IV Social Anxiety Disorders, *Depression and Anxiety*, 2008; 25:230-240.

Covey LS, Glassman AH, Jiang H, Fried J, Masmela J, LoDuca C, Petkova E, Rodriguez K. A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse. *Addiction*. 2007 Aug;102(8):1292-302.

Covey LS, Botello-Harbaum, Glassman AH, Masmela J, LoDuca C, Salzman V. Smokers' response to combination treatment with bupropion, nicotine patch, and individual counseling treatment. *Ethnicity and Disease*. V. 18, Winter 2008.

Cullen B, Samuels JF, Pinto A, Fyer AJ, McCracken JT, Rauch SL, Murphy DL, Greenberg BD, Knowles JA, Piacentini J, Bienvenu OJ 3rd, Grados MA, Riddle MA, Rasmussen SA, Pauls DL, Willour VL, Shugart YY, Liang KY, Hoehn-Saric R, Nestadt G. (2008). Demographic and clinical characteristics associated with treatment status in family members with obsessive-compulsive disorder. *Depress Anxiety*, 25(3):218-224.

Devlin MJ, Allison KC, Goldfein JA, Spanos A. Management of Eating Disorders Not Otherwise Specified. In: Yager J, Powers PS (Eds.). *Clinical Manual of Eating Disorders*. American Psychiatric Publishing, Washington DC, 2007, pp. 223-256.

Devlin MJ, Goldfein JA, Petkova E, Liu L, Walsh BT. Cognitive behavioral therapy and fluoxetine for binge eating disorder: two-year follow-up. *Obesity Research* 15: 1702-1709, 2007.

Devlin MJ, Goldfein JA, Petkova E, Raizman P, Wolk S, Mayer L, Carino J, Bellace D, Kamenetz C, Dobrow I, Walsh BT. Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder. *Obesity* 15: 1702 – 1709, 2007.

Devlin MJ, Goldfein JA, Petkova E, Liu L, Walsh BT. Cognitive behavioral therapy and fluoxetine for binge eating disorder: two-year follow-up. *Obesity* 15:1702-1709, 2007.

Devlin MJ. Is there a place for obesity in DSM-V? *International Journal of Eating Disorders* 40:S83-S88, 2007.

Dohrenwend BP, Turner JB, Turse NA, Lewis-Fernández R, Yager TJ. War-related PTSD in Black, Hispanic, and majority White Vietnam veterans: the roles of exposure vulnerability factors, *J Traumatic Stress*, 2008, 21, 133-141.

Dominguez J, Goodman L, Sen Gupta S, Mayer L, Etu SF, Walsh BT, Wang J, Pierson R, Warren MP: Treatment of anorexia nervosa is associated with increases in bone mineral density, and recovery is a biphasic process involving both nutrition and return of menses. *Am J Clin Nutr* 86: 92-97, 2007.

Dunlop BW, Papp LA, Garlow SJ, Weiss PS, Knight BT, Ninan PT: Tiagabine for Social Anxiety Disorder. *Human Psychopharmacology: Clinical & Experimental*, 2007; 22(4): 241-244.

Glassman AH, Miller GE. Where there is depression, there is inflammation...sometimes! *Biol Psychiatry*. 2007 Aug 15;62(4):280-281.

Fyer, A.J. (In Press). Anxiety Disorders: Genetics. In: HI Kaplan, BJ Sadock (eds.), *Comprehensive Textbook of Psychiatry* (9th ed.). Baltimore: Lippincott Williams and Wilkins.

Gafoori, B., Neria, Y, Olfson, M., Gameraff, MJ, Lantigua, R., Shea, S., Weissman, MM,. Screening of Generalized Anxiety Disorder After Terrorist Attacks: A study in Primary Care. *Journal of Traumatic Stress*. (In Press).

Glassman AH, Bigger JT, Gaffney M, Van Zyl L. Heart rate variability in acute coronary syndrome patients with major depression: influence of sertraline and mood improvement. *Arch Gen Psychiatry* 2007 Sep;64(9):1025-1031.

Glassman AH. Vascular disease and depression: clinical management. *European Neuropsychopharmacology ECNP*, V. 17 Supp 4, P.S212, Abstract from 20th ECNP Congress, 13-17 October 2007, Vienna, Austria.

Glassman AH. Depression and Cardiovascular Disease. *Pharmacopsychiatry* 2008; 41:1-5.

Glassman AG. Special Populations in Depression. *Clinical Implications of Depression in Patients with Cardiovascular Disease. Practical Neuroscience for Primary Care Physicians*. Summer (S) 2008 p. 5-8.

Gorenstein EE, Papp LA: Cognitive-behavioral therapy for anxiety in the elderly. *Current Psychiatry Reports* 2007; 9(1):20-5.

Gorenstein, E. E., & Comer, R. J., (2nd edition, in preparation) *Case studies in abnormal psychology*. Boston: Worth Publishers, Inc.

Guarnaccia PJ, Martinez-Pincay I, Alegría M, Shrout P, Lewis-Fernández R, Canino GJ. Assessing diversity among Latinos: Results from the NLAAS. *Hispanic Journal of Behavioral Sciences*, 2007, 29:510-534.

Haney M, Gunderson EW, Rabkin J, Hart C, Vosburg S, Comer S, Foltin R: Dronabinol and marijuana in HIV+ marijuana smokers: caloric intake, mood and sleep. *J Acquir Immune Defic Syndrom* 2007; 45:545-554

Hellerstein DJ, Almeida G, Devlin MJ, Mendelsohn N, Helfand S, Dragatsi D, Miranda R, Kelso JR, Capitelli L. Assessing obesity and other related health problems of mentally ill Hispanic patients in an urban outpatient setting. *Psychiatric Quarterly* 78:171-181, 2007.

Hellerstein DJ, Batchelder S, Hyler S, Arnaout B, Corpuz V, Coram L, Weiss G: Aripiprazole as an adjunctive treatment for refractory unipolar depression. *Progress in Neuropsychopharmacology and Biological Psychiatry* 2008;32:744-750

Hellerstein DJ: Evidence-based practice and practice-based evidence in psychiatry. *The Medscape Journal of Medicine* 2008; 10:141

Hellerstein DJ, Markowitz JC: Supportive psychotherapy as an evidence-based treatment (letter). *American J of Psychiatry* 2008;165:1355-1356

Hellerstein DJ, Seirmarco G, Almeida G, Batchelder S. Assessing behavioral coping preferences of psychiatric inpatients: a pilot study. *Medscape Journal of Medicine* 2008 (in press)

Hellerstein DJ: Supportive psychotherapy of a depressed 49-year-old man. In: *Approaches to the Psychiatric Patient*, ed. John Barnhill. American Psychiatric Press, Washington DC, 2008, 46-49

Hellerstein DJ: Combining supportive psychotherapy with medication. *The American Psychiatric Publishing Textbook of Psychotherapeutic Treatments in Psychiatry*, ed. Glen Gabbard, section on Supportive Psychotherapy, section editor Arnold Winston. American Psychiatric Press, Washington DC, 2008, 595-629

Hobfoll S, Watson P, Ruzek J Bell, Bryant R, Brymer MJ, Pynoos RS, Steinberg AM, Friedman M J, Friedman M, Gersons B PR, de Jong JTVM, Maguen S, Neria Y, Norwood A E, Reissman D, Shalev A Y, Solomon Z, Ursano R J. Five Essential Elements of Immediate and Mid-Term Mass Trauma Intervention: Empirical Evidence. *Psychiatry*. Vol. 70. 2007. (pp. 283-315).

Hodges LM, Weissman MM, Haghghi F, Costa R, Bravo O, Evgrafov O, Knowles JA, Fyer AJ, Hamilton SP. Association and linkage analysis of candidate genes GRP, GRPR, CRHR1, and TACR1 in panic disorder. *Am J Med Genet B Neuropsychiatr Gene*, 2008 May 1.

Jacobs-Pilipski MJ, Wilfley DE, Crow SJ, Walsh BT, Lilenfeld LRR, West DS, Berkowitz RI, Fairburn CG: Placebo response in binge eating disorder. *International Journal of Eating Disorders*. 40: 204-211, 2007.

Javaras KN, Pope HG, Lalonde JK, Roberts JL, Nillni YI, Laird NM, Bulik CM, Crow SJ, McElroy SL, Walsh BT, Tsuang MT, Rosenthal NR, Hudson JI.

Co-occurrence of binge eating disorder with psychiatric and medical disorders. *J Clin Psychiatry*. 2008 Feb;69(2):266-73.

Kissileff HR, Zimmerli EJ, Torres MJ, Devlin MJ, Walsh BT. Effect of eating rate on binge size in bulimia nervosa. *Physiology and Behavior* 93:481-485, 2008.

Klein DA, Schebendach JE, Brown AJ, Smith GP, Walsh BT. Modified sham feeding of sweet solutions in women with and without bulimia nervosa. *Physiol Behav*. 2008 Aug 17

Klein, DA; Schebendach, JS; Foltin, RW; Walsh, BT. Translational Studies on Exercise Behavior in Anorexia Nervosa. Paper presented at the 13th annual meeting of the Eating Disorder Research Society, Pittsburgh, PA, Oct 27, 2007.

Klein DA, Mayer LE, Schebendach JE, Walsh BT. Authors' reply. *Psychoneuroendocrinology*. 2007 Sep-Nov;32(8-10):1166. Epub 2007 Sep 21.

Klein, DA; Schebendach, JS; Brown, AJ; Smith, GP; Walsh, BT. Modified Sham Feeding (MSF) in Women with and without Eating Disorders. Poster presentation, Annual Meeting of the Society for the Study of Ingestive Behavior, Paris, France, July 2008.

Knijnik DZ, Blanco C, Salum GA, Moraes CU, Mombach C, Almeida E, Pereira M, Strapasson A, Manfro GG, Eizirik CL. A pilot study of clonazepam versus psychodynamic group therapy plus clonazepam in the treatment of generalized social anxiety disorder. *Eur Psychiatry*, 2008 (in press).

Kim SW, Grant JE, Potenza MC, Blanco C, Hollander E. The Gambling Symptom Assessment Scale (G-SAS): A reliability and validity study. *Psychiatry Res* (in press)

Kinoshita Y, Chen J, Rapee RM, Bögels S, , Schneier FR, Choy Y, Kwon J, Liu X, Shramm L, Chavira DA, Nakano Y, Wantanbe N, Ietzugu T, Ogawa S, Emmelkamp P, Zhang J, Kingdon D, Nagata T, Furukawa TA: Cross-cultural study of conviction subtype Taijin Kyofu: proposal and reliability of Nagoya-Osaka diagnostic criteria for social anxiety disorder. *Journal of Nervous and Mental Disease*, 2008;196: 307-313.

Kraft JB, Peters EJ, Slager SL, Jenkins GD, Reinalda MS, McGrath PJ, Hamilton SP: Analysis of association between the serotonin transported and antidepressant response in a large clinical sample. *Biol Psychiatry* 2007; 61:734-742

Levin, FR, Bisaga, A, Raby, W, Aharonovich, E, Rubin, E, Mariani, J, Brooks, DJ, Garawi, F, Nunes, EV: Effects of major depressive disorder and attention-deficit/hyperactivity disorder on the outcome of treatment for cocaine dependence. *J Subst Abuse Treat* 2008; 34: 80-89

Lewis-Fernández R, Turner JB, Marshall RD, Turse N, Neria Y, Dohrenwend BP. Elevated rates of current PTSD among Hispanic veterans in the NVVRS: True prevalence or methodological artifact? *J Traumatic Stress*, 2008, 21:123-132.

Lewis-Fernández R, Horvitz-Lennon M, Blanco C, Guarnaccia PJ, Cao Z, Alegria M. Significance of endorsement of psychotic symptoms by US Latinos. *Journal of Nervous and Mental Disease*, in press.

Liang KY, Wang Y, Shugart YY, Grados M, Fyer AJ, Rauch S, Murphy D, McCracken J, Rasmussen S, Cullen B, Hoehn-Saric R, Greenberg B, Pinto A, Knowles J, Piacentini J, Pauls D, Bienvenu O, Riddle M, Samuels J, Nestadt G. (2008). Evidence for potential relationship between SLC1A1 and a putative genetic linkage region on chromosome 14q to obsessive-compulsive disorder with compulsive hoarding. *Am J Med Genet B Neuropsychiatr Genet*, 147B(6), 1000-1002.

Lipsitz JD, Gur M, Vermes D, Petkova E, Cheng J, Miller N, Laino J, Liebowitz MR, Fyer AJ. (2008). A randomized trial of interpersonal therapy versus supportive therapy for social anxiety disorder. *Depress Anxiety*, 25(6), 542-553.

Loeb KL, Walsh BT, Lock J, LeGrange D, Jones J, Marcus S, Weaver J, Dobrow I: Open Trial of Family-Based Treatment for Full and Partial Anorexia Nervosa in Adolescence: Evidence of Successful Dissemination. *JAACAP*. in press.

Mariani, JJ, Horey, J, Bisaga, A, Aharonovich, E, Raby, W, Cheng, WY, Nunes, E, Levin, FR: Antisocial behavioral syndromes in cocaine and cannabis dependence. *Am J Drug Alcohol Abuse* 2008; 34: 405-414

Marsh R, Steinglass JE, Gerber AJ, O'Leary KG, Wang Z, Murphy D, Walsh BT, Peterson BS, (in press) "Deficient activity in the neural systems that mediate self-regulatory control in bulimia nervosa," *Archives of General Psychiatry*

Mayer LE, Roberto CA, Glasofer DR, Etu SF, Gallagher D, Wang J, Heymsfield SB, Pierson RN Jr., Attia E, Devlin MJ, Walsh BT. Does percent body fat predict outcome in anorexia nervosa? *American Journal of Psychiatry* 164:970-972, 2007.

McCarty, D, Fuller, B, Kaskutas, LA, Wendt, WW, Nunes, EV, Miller, M, Forman, R, Magruder, KM, Arfken, C, Copersino, M, Floyd, A, Sindelar, J, Edmundson, E: Treatment programs in the National Drug Abuse Treatment Clinical Trials Network. *Drug Alcohol Depend* 2008; 92: 200-207

McElhiney M, Chew S, Gordon P, Rabkin J, Mitsumoto H: Prevalence and relationship of fatigue and depression in ALS patients. *Amyotrophic Lateral Sclerosis* 2007; 8(suppl 1):95

Mitchell JE, Devlin MJ, de Zwaan M, Crow SJ, Peterson CB. *Binge Eating Disorder: Clinical Foundations and Treatment*. Guilford Publications, New York, 2008.

Mitsumoto H, Rabkin JG: Palliative care for patients with amyotrophic lateral sclerosis. JAMA 2007; 298:207-216

Moadel AB, Shah C, Wylie-Rosett J, Harris MS, Patel SR, Hall CB, Sparano JA. Randomized controlled trial of Yoga among a multiethnic sample of breast cancer patients: Effects on quality of life. Journal of Clinical Oncology, 2007; 25 (28): 4387-4395.

Neria Y, Nandi A, Galea S. Posttraumatic Stress Disorder Following Disasters: A Systematic Review, Psychological Medicine. Vol. 38. 2008. (pp. 467-480).

Neria Y, Olfson M, Gameroff M, Gross R, Pilowsky D, Blanco C, Manetti-Cusa J, Wickramaratne, Lantigua R, Shea S, Weissman MM. The Mental Health Sequelae of Loss: Findings from a New York City Primary Care Practice One Year after the 9/11 Attacks. Psychiatry. (In Press)

Neria Y, Olfson M, Gameroff M, Wickramaratne P, Pilowsky D, Verdelli H, Gross R, Manetti-Cusa J, Marshall RD, Lantigua L, Shea S, Weissman MM. Trauma exposure and Posttraumatic Stress Disorder in Primary Care Patients with Bipolar Spectrum Disorder. Bipolar Disorders. Vol 10. 2008 (pp. 503-510).

Papa, T, Neria, Y, Litz, B. Traumatic Bereavement in War Veterans. Psychiatric Annals. Vol 38, 2008.

Papp LA: Generalized Anxiety Disorder; Evaluation and Diagnosis. In Barnhill (ed.) Approach to the Psychiatric Patient. American Psychiatric Press, Washington DC 2008.

Papp LA: Pharmacological approach to the management of stress and anxiety disorders. In Lehrer, Woolfolk (eds.) Principles and Practice of Stress Management (Third Edition) 2007; The Guilford Press, New York

Papp LA: Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study. Journal of Clinical Psychiatry 2006; 67(10): 1573-6.

Papp LA, Goetz R, Reynoso MB: Benefits of venlafaxine in late-life anxiety. (in review)

Papp LA, Ray S: The SGRI tiagabine for the treatment of generalized anxiety disorder. (in review)

Patel SR, Carmody J, Simpson HB. Adapting Mindfulness Based Stress Reduction for the treatment of Obsessive Compulsive Disorder: A case report . Cognitive and Behavioral Practice, 2007; 14, 375-380.

Rabkin JG, Gordon P, McElhiney M, Rabkin R, Chew S, Mitsumoto H: Modafinil for treatment of fatigue in ALS patients: pilot study. *Amyotrophic Lateral Sclerosis* 2007; 8 (suppl 1): 96-97

Reid, MS, Fallon, B, Sonne, S, Flammino, F, Nunes, EV, Jiang, H, Kourniotis, E, Lima, J, Brady, R, Burgess, C, Arfken, C, Pihlgren, E, Giordano, L, Starosta, A, Robinson, J, Rotrosen, J: Smoking cessation treatment in community-based substance abuse rehabilitation programs. *J Subst Abuse Treat* 2008; 35, 68-77

Roberto CA, Steinglass J, Mayer L, Attia E, Walsh BT. "The Clinical Significance of Amenorrhea as a Diagnostic Criterion for Anorexia Nervosa." *International Journal of Eating Disorders*, 2008, 41(6):559-63.

Ruggiero, JK, Neria, Y, Gross, YR, Galea S. Posttraumatic Stress Disorder. *BMJ, Point of Care*. (In Press).

Rutherford B, Hellerstein DJ: Divergent fates of the medical humanities in psychiatry and internal medicine: should psychiatry be rehumanized? *Academic Psychiatry* 2008;32:206-213

Schebendach JE, Klein DA, Foltin RW, Devlin MJ, Walsh BT. Relative reinforcing value of exercise in inpatients with anorexia nervosa: model development and pilot data. *Int J Eat Disord*. 2007 Jul;40(5):446-53.

Schebendach JE, Klein DA, Foltin RW, Devlin MJ, Walsh BT. Relative reinforcing value of exercise in inpatients with anorexia nervosa: model development and pilot data. *International Journal of Eating Disorders* 40:446-453, 2007.

Schebendach JE, Mayer LES, Devlin MJ, Attia E, Contento IR, Wolf RL, Walsh BT. Dietary energy density and diet variety as predictors of outcome in anorexia nervosa. *American Journal of Clinical Nutrition* 87:810-816, 2008.

Schneier FR, Erwin BA, Erwin BA, Heimberg, Marshall RD, Mellman LA: Social anxiety disorder and specific phobias. In Gabbard GO (ed.) *Treatment of Psychiatric Disorders*, Fourth Edition. 2007; pp. 495-506. American Psychiatric Publishing, Washington, D.C.

Schneier FR, Martinez D, Abi-Dargham A, Zea-Ponce Y, Simpson HB, Liebowitz MR, Laruelle M: Striatal dopamine D2 receptor availability in OCD with and without comorbid social anxiety disorder: Preliminary findings. *Depression and Anxiety*, 2008;25: 1-7.

Simpson HB, Foa EB, Liebowitz MR et al: CBT Augmentation of SRI Pharmacotherapy in OCD: a multi-site randomized controlled trial. *American Journal of Psychiatry* 2008;165:621-630

Simpson HB, Petkova E, Cheng J, Huppert H, Foa EB, Liebowitz MR.: Statistical models can affect inferences from clinical trials: a case study from obsessive-compulsive disorder research. *Journal of Psychiatric Research* 2008; 42(8):631-638.

Simpson HB, Zuckoff AM, Page JR, Franklin ME, Foa EB: Adding Motivational Interviewing to Exposure and Ritual Prevention for Obsessive-Compulsive Disorder: An open pilot trial. *Cognitive Behaviour Therapy* 2008; 37(1):38-49.

Sinha SA, Schneier F: Pharmacology of anxiety. In Barnhill JW (ed.) *Approach to the Psychiatric Patient: Case-Based Essays*. 2008, pp. 313-314. American Psychiatric Publishing, Washington, DC.

Sinha SS, Goetz RG, Klein DF. Physiological and Behavioral effects of naloxone and lactate in normal volunteers with relevance to the pathophysiology of panic disorder. *Psychiatry Research* 149 (2007) 309-314.

Steinglass, JE, Sysko, R, Schebendach, J, Broft, A, Strober, M, Walsh, BT, "The application of exposure therapy and D-cycloserine to the treatment of anorexia nervosa: a preliminary trial," *Journal of Psychiatric Practice*, 2007, 13(4):238-245.

Steinglass JE, Albano AM, Simpson HB, Walsh BT, "Development of Exposure Therapy and Ritual Prevention for Anorexia Nervosa," *Eating Disorders Research Society*, Pittsburgh, October, 2007.

Steinglass JE, Eisen JL, Attia E, Mayer L, Walsh BT: Is anorexia nervosa a delusional disorder? An assessment of eating beliefs in anorexia nervosa. *J Psychiatr Pract*. 13: 65-7, 2007

Stewart JW, McGrath PJ, Quitkin FM, Klein DF: Atypical depression: current status and relevance to melancholia: *Acta Psychiatrica Scandinavia* 2007; 115(suppl 433):58-71

Stewart, JW, Thase, ME: Treating DSM-IV depression with atypical features. *J Clin Psychiatry* 2007; 68:e10

Sysko R, Devlin MJ, Walsh BT, Zimmerli E, Kissileff HR. Satiety and test meal intake among women with binge eating disorder. *International Journal of Eating Disorders* 40:554-561, 2007.

Sysko R, Walsh BT: A critical evaluation of the efficacy of self-help interventions for the treatment of bulimia nervosa and binge eating disorder. *International Journal of Eating Disorders*. In press.

Sysko R, Walsh BT, Wilson GT: Expectancies, dietary restraint, and test meal intake among undergraduate women. *Appetite* 49: 30 – 37, 2007.

Talati A, Fyer AJ, Weissman MM. (2008). A comparison between screened NIMH and clinically interviewed control samples on neuroticism and extraversion. *Mol Psychiatry*, 13(2), 122-130.

Talati A, Ponniah K, Strug LJ, Hodge SE, Fyer AJ, Weissman MM. (2008). Panic disorder, social anxiety disorder, and a possible medical syndrome previously linked to chromosome 13. *Biol Psychiatry*, 63(6), 594-601.

Thase ME, Friedman ES, Biggs MM, Wisniewski SR, Trivedi MH, Luther JF, Fava M, Nierenberg AA, McGrath PJ, Warden D, Niederehe G, Hollon SD, Rush AJ: Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: A STAR\*D report. *Am J Psychiatry* 2007; 164: 739-752

Sullivan, G. and Neria, Y. Pharmacotherapy in Posttraumatic Stress Disorder: Evidence from Randomized Controlled Trials. *Current Opinions in Investigational Drugs*. (In Press)

Van Gorp W, Rabkin JG, Ferrando SJ, Mintz J, Ryan E, Borkowski T, McElhiney M: Neuropsychiatric predictors of return to work in HIV/AIDS. *Journal of the International Neuropsychological Society*, 2007; 13:80-89

Vega WA, Lewis-Fernández R. Ethnicity and variability of psychotic symptoms. *Current Psychiatry Reports*, in press.

Vesga O, Blanco C. IPT and medication. In: Gabbard GO, ed. *American Psychiatric Association Textbook of Psychotherapy*. Washington, D.C.: American Psychiatric Publishing, Inc., 2008 p.365-388

Vesga-López O, Schneier FR, Wang S, Heimberg RG, Liu SM, Hasin DS, Blanco C. Gender differences in Generalized Anxiety Disorder: Results from the National Epidemiologic Study on Alcohol and Related Conditions. *J Clin Psychiatry* (in press).

Vesga-López O, Blanco C, Keyes KM, Olfson M, Grant BF, Hasin DS. Psychiatric Disorders in Pregnant and Postpartum Women in the United States. *Arch Gen Psychiatry*, 2008; 65:805-815.

Vega WA, Karno M, Alegría M, Alvidrez J, Bernal G, Escamilla M, Escobar J, Guarnaccia P, Jenkins J, Kopelowicz A, Lagomasino IT, Lewis-Fernández R, Marín H, López S, Loue S. Research issues for improving treatment of US Hispanics with persistent mental disorder. *Psychiatric Services*, 2007, 58:385-394.

Walsh BT: DSM-V from the perspective of the DSM-IV experience. *International Journal of Eating Disorders*. In press.

Wang Y, Samuels JF, Chang YC, Grados MA, Greenberg BD, Knowles JA, McCracken JT, Rauch SL, Murphy DL, Rasmussen SA, Cullen B, Hoehn-Saric R, Pinto A, Fyer AJ,

Piacentini J, Pauls DL, Bienvenu OJ, Riddle M, Shugart YY, Liang KY, Nestadt G. Gender differences in genetic linkage and association on 11p15 in obsessive-compulsive disorder families. *Am J Med Genet B Neuropsychiatr Genet.* 2008 Apr 18.

Wilfley DE, Crow SJ, Hudson JI, Mitchell JE, Berkowitz RI, Blakesley V, Walsh BT, The Sibutramine Binge Eating Research Group. Efficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind study. *Am J Psychiatry* 165: 51-58, 2008.

Wisniewski SR, Fava M, Trivedi MH, Thase ME, Warden D, Niederehe G, Friedman ES, Biggs MM, Sackeim HA, Shores-Wilson K, McGrath PJ, Lavori PW, Miyahara S, Rush AJ: Acceptability of second-step treatments to depressed outpatients: A STAR\*D report. *Am J Psychiatry* 2007; 164: 753-760